Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (ESPR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ESPR · as of Sep 30, 2025
Ownership Breakdown
201
Institutional Holders
▲ 31 vs Q2
$286.21M
Total Inst. Value
▲ $187.05M vs Q2
207.91M
Shares Outstanding
freeFloat 100.00%
108.00M
13F Shares Held
▲ 9.78M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ESPR largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 14.83M | 7.54% | 7.54% | $39.31B | Nov 12, 2025 | ▲ 120.7K |
VANGUARD GROUP INC pharmaceutical preparations | 12.09M | 6.14% | 6.14% | $32.04B | Nov 7, 2025 | ▲ 375.6K |
TWO SEAS CAPITAL LP pharmaceutical preparations | 9.75M | 4.95% | 4.95% | $25.84B | Nov 14, 2025 | ▼ 205.3K |
WASATCH ADVISORS LP pharmaceutical preparations | 7.06M | 3.59% | 3.59% | $18.71B | Nov 14, 2025 | ▼ 3.28M |
PENDERFUND CAPITAL MANAGEMENT LTD. pharmaceutical preparations | 6.68M | 3.39% | 3.39% | $17.69B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 4.75M | 2.41% | 2.41% | $12.59B | Nov 12, 2025 | ▲ 167.4K |
STATE STREET CORP pharmaceutical preparations | 4.48M | 2.28% | 2.28% | $11.87B | Nov 14, 2025 | ▲ 720.1K |
MORGAN STANLEY pharmaceutical preparations | 4.06M | 2.06% | 2.06% | $10.75B | May 27, 2026 | ▲ 3.00M |
NUVEEN, LLC pharmaceutical preparations | 3.71M | 1.89% | 1.89% | $9.83B | Nov 12, 2025 | ▲ 3.29M |
AIGH CAPITAL MANAGEMENT LLC pharmaceutical preparations | 3.00M | 1.52% | 1.52% | $7.95B | Oct 31, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
27
Increased
+14.44M shares6
New Positions
first time holders13
Decreased
−10.03M shares0
Sold Out
fully exitedNet shares change (top 50)
+4.41M
+14.44M / −10.03M
Net new holders
+20
6 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ESPR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
4
Sell transactions
1.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
THOMPSON JOHN CRAIG director | May 28, 2026 | Award | 79,873 | — | — | 79.9K | Form 4 ↗ |
Shepard Jay director | May 28, 2026 | Award | 79,873 | — | — | 164.5K | Form 4 ↗ |
Hoffman Robert E. director | May 28, 2026 | Award | 79,873 | — | — | 85.2K | Form 4 ↗ |
Fischer Seth H. Z. director | May 28, 2026 | Award | 79,873 | — | — | 141.0K | Form 4 ↗ |
CARROLL J MARTIN director | May 28, 2026 | Award | 79,873 | — | — | 177.5K | Form 4 ↗ |
Looker Benjamin Chief Legal Officer | Mar 17, 2026 | Sale | 5,708 | $2.70 | $15.4K | 679.3K | Form 4 ↗ |
Koenig Sheldon L. President and CEO | Mar 17, 2026 | Sale | 25,578 | $2.72 | $69.5K | 2.17M | Form 4 ↗ |
Halladay Benjamin Chief Financial Officer | Mar 17, 2026 | Sale | 6,424 | $2.71 | $17.4K | 713.6K | Form 4 ↗ |
Looker Benjamin Chief Legal Officer | Mar 13, 2026 | Award | 300,840 | — | — | 685.1K | Form 4 ↗ |
Looker Benjamin Chief Legal Officer | Mar 13, 2026 | Award | 269,230 | $2.44 | $656.9K | 269.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Esperion Therapeutics, Inc. (ESPR) is primarily owned by institutional investors, who hold approximately 52.0% of total shares outstanding. Company insiders own approximately 0.00%, while retail and public investors account for the remaining 48.05%.
The largest institutional shareholder of Esperion Therapeutics, Inc. is BLACKROCK, INC., holding approximately 14.83 million shares — equal to 7.54% of outstanding shares — as of September 30, 2025.
A total of 201 institutional investors currently hold ESPR stock, with a combined institutional value of approximately $286,207,472 as of the most recent 13F filing period.
Frequently asked questions
ESPR ownershipEsperion Therapeutics, Inc. (ESPR) is primarily owned by institutional investors, who hold approximately 52.0% of shares. The largest shareholder is BLACKROCK, INC. with a 7.54% stake. Company insiders hold 0.00%. Data sourced from SEC Form 13F as of September 30, 2025.